S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
OTCMKTS:BMXMF

bioMérieux (BMXMF) Stock Price, News & Analysis

$109.51
-1.74 (-1.56%)
(As of 04/12/2024 ET)
Today's Range
$109.51
$111.75
50-Day Range
$102.85
$113.38
52-Week Range
$90.23
$115.25
Volume
185 shs
Average Volume
12 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BMXMF stock logo

About bioMérieux Stock (OTCMKTS:BMXMF)

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

BMXMF Stock Price History

BMXMF Stock News Headlines

bioMérieux (OTCMKTS:BMXMF) Stock Price Down 5.3%
Biomerieux/adr's Net Worth
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
bioMerieux : du mieux
bioMerieux recule après les annonces
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
See More Headlines
Receive BMXMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:BMXMF
CIK
N/A
Employees
13,800
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.98 billion
Cash Flow
$5.80 per share
Book Value
$32.43 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.87
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Pierre Boulud (Age 53)
    Chief Executive Officer
    Comp: $1.13M
  • Mr. Frederic Beseme (Age 68)
    Head of CSR
    Comp: $23.82k
  • Mr. Guillaume Bouhours (Age 48)
    Executive VP of Purchasing and Information Systems & CFO
  • Sylvain Morgeau
    Investor Relations
  • Ms. Audrey Dauvet (Age 50)
    Executive Vice President of Legal Affairs & Integrity
  • Ms. Valerie Leylde
    Executive Vice President of Human Resources, Communications & CSR
  • Mr. Pierre Charbonnier
    Executive Vice President of Global Quality, Manufacturing & Supply Chain
  • Mr. Yasha Mitrotti
    Executive Vice President of Industrial Applications
  • Jennifer Zinn
    Executive Vice President of Clinical Operations
  • Charles K. Cooper
    Executive VP & Chief Medical Officer

BMXMF Stock Analysis - Frequently Asked Questions

Should I buy or sell bioMérieux stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bioMérieux in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BMXMF shares.
View BMXMF analyst ratings
or view top-rated stocks.

How have BMXMF shares performed in 2024?

bioMérieux's stock was trading at $108.50 at the start of the year. Since then, BMXMF shares have increased by 0.9% and is now trading at $109.51.
View the best growth stocks for 2024 here
.

How do I buy shares of bioMérieux?

Shares of BMXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BMXMF) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners